BioAtla (BCAB) Revenue & Revenue Breakdown
BioAtla Revenue Highlights
BioAtla Revenue by Period
BioAtla Revenue by Year
Date | Revenue | Change |
---|---|---|
2023-12-31 | - | 100.00% |
2022-12-31 | - | -100.00% |
2021-12-31 | $250.00K | -41.72% |
2020-12-31 | $429.00K | -91.75% |
2019-12-31 | $5.20M | -51.07% |
2018-12-31 | $10.63M | - |
BioAtla Revenue by Quarter
Date | Revenue | Change |
---|---|---|
2024-06-30 | - | 100.00% |
2024-03-31 | - | -100.00% |
2023-12-31 | $1.71M | 100.00% |
2023-09-30 | - | 100.00% |
2023-06-30 | - | 100.00% |
2023-03-31 | - | 100.00% |
2022-12-31 | - | 100.00% |
2022-09-30 | - | 100.00% |
2022-06-30 | - | 100.00% |
2022-03-31 | - | -100.00% |
2021-12-31 | $250.00K | 66.67% |
2021-09-30 | $150.00K | -40.00% |
2021-06-30 | $250.00K | 100.00% |
2021-03-31 | - | 100.00% |
2020-12-31 | - | -100.00% |
2020-09-30 | $150.00K | -21.05% |
2020-06-30 | $190.00K | 113.48% |
2020-03-31 | $89.00K | -95.96% |
2019-12-31 | $2.20M | - |
BioAtla Revenue Breakdown
BioAtla Revenue Breakdown by Product
Quarterly Revenue by Product
Product/Service | Jun 21 |
---|---|
Service | $300.00K |
BioAtla Revenue Breakdown by Country
Quarterly Revenue by Country
Country | Jun 21 |
---|---|
Service | $300.00K |
BioAtla Peer Comparison by Revenue
Ticker | Company | Last Year Revenue | Last Quarter Revenue |
---|---|---|---|
KYMR | Kymera Therapeutics | $78.59M | $3.74M |
NRIX | Nurix Therapeutics | $76.99M | $12.59M |
FHTX | Foghorn Therapeutics | $34.16M | $6.89M |
ADAG | Adagene | $18.11M | $833.34K |
IKNA | Ikena Oncology | $9.16M | - |
IPSC | Century Therapeutics | $2.23M | $771.00K |
STTK | Shattuck Labs | $1.66M | $1.61M |
DSGN | Design Therapeutics | - | - |
RZLT | Rezolute | - | - |
CCCC | C4 Therapeutics | - | - |
ANTX | AN2 Therapeutics | - | - |
GRCL | Gracell Bio | - | - |
BCAB | BioAtla | - | - |
AVTE | Aerovate Therapeutics | - | - |
OLMA | Olema Pharmaceuticals | - | - |
ERAS | Erasca | - | - |
PASG | Passage Bio | - | - |
ACRV | Acrivon Therapeutics | - | - |
PMVP | PMV Pharmaceuticals | - | - |
GLUE | Monte Rosa Therapeutics | - | $4.70M |
NAUT | Nautilus Bio | - | - |
BCAB Revenue FAQ
What is BioAtla’s yearly revenue?
BioAtla's yearly revenue for 2023 was $0, representing an increase of 100.00% compared to 2022. The company's yearly revenue for 2022 was $0, representing a decrease of -100.00% compared to 2021. BCAB's yearly revenue for 2021 was $250K, representing a decrease of -41.72% compared to 2020.
What is BioAtla’s quarterly revenue?
BioAtla's quarterly revenue for Q2 2024 was $0, a 100.00% increase from the previous quarter (Q1 2024), and a 0% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $0, a -100.00% decrease from the previous quarter (Q4 2023), and a 0% increase year-over-year (Q1 2023). BCAB's quarterly revenue for Q4 2023 was $1.71M, a 100.00% increase from the previous quarter (Q3 2023), and a 0% increase year-over-year (Q4 2022).
What is BioAtla’s revenue growth rate?
BioAtla's revenue growth rate for the last 3 years (2021-2023) was -100.00%, and for the last 5 years (2019-2023) was -100.00%.